Skip to content
ADX BLADDER Performance Evaluation for diagnosis of bladder cancer in patients with haematuria 1
Blinded prospective study Including patients presenting with haematuria and/or lower urinary tract symptoms ADXBLADDER vs Cystoscopy, imaging and biopsy results Carried out at 7 leading UK Centres 856 patients recruited
(excl. LGpTa) 85%
Excluding Low Grade pTa tumours
80% sensitivity for Upper Tract Transitional Cell Carcinomas (TCCs) such as those of the Ureters and Kidney, which can be difficult to detect with cystoscopy or ultrasound.
ADXBLADDER Performance Evaluation in bladder cancer follow-up
Blinded prospective study Including patients in the first 2 years of follow up after a primary or recurrent bladder tumour ADXBLADDER vs Cystoscopy, Cytology and Pathology Carried out at 21 leading European Centres 2000 patients recruitment target Study closed at the end of July 2019. Data referred to interim analysis of 1192 pts 362 samples had matching Cytology data 39 were positive for bladder cancer recurrence (9 were non-LGpTa Recurrences)
ADX BLADDER clinical performance Sensitivity
(excl LGpTa) 84% NPV
(excl. LGpTa) 99.5%
ADX BLADDER performance vs cytology Excl LGpTa tumours
Dudderidge T, et al. A Novel, non-invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Patients Presenting with Haematuria—A Prospective Multicentre Performance Evaluation of ADXBLADDER. Eur Urol Oncol (2019), https://doi.org/10.1016/j.euo.2019.06.006
more information Accept
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
For more details, please read our privacy statement Close